The BET Bromodomain Inhibitor OTX015 Affects Pathogenetic Pathways in Preclinical B-cell Tumor Models and Synergizes with Targeted Drugs
暂无分享,去创建一个
L. Cascione | P. Hérait | G. Inghirami | A. Stathis | E. Gaudio | E. Zucca | A. Mensah | I. Kwee | F. Bertoni | M. Ponzoni | G. Stussi | P. Bonetti | C. Tarantelli | M. Riveiro | A. Rinaldi | E. Cvitkovic | M. Testoni | M. Boi | E. Bernasconi
[1] L. Cascione,et al. Novel HDAC inhibitors exhibit pre-clinical efficacy in lymphoma models and point to the importance of CDKN1A expression levels in mediating their anti-tumor response , 2014, Oncotarget.
[2] A. Palumbo,et al. 5LBA Results of a first-in-man phase I trial assessing OTX015, an orally available BET-bromodomain (BRD) inhibitor, in advanced hematologic malignancies , 2014 .
[3] H. Dombret,et al. Abstract LB-231: A phase I pharmacokinetic study of OTX015 for the treatment of patients with hematologic malignancies , 2014 .
[4] Paul Shinn,et al. Blockade of oncogenic IκB kinase activity in diffuse large B-cell lymphoma by bromodomain and extraterminal domain protein inhibitors , 2014, Proceedings of the National Academy of Sciences.
[5] Hong Zhang,et al. Inhibition of Bromodomain Proteins for the Treatment of Human Diffuse Large B-cell Lymphoma , 2014, Clinical Cancer Research.
[6] Zhoulei Li,et al. BET and HDAC inhibitors induce similar genes and biological effects and synergize to kill in Myc-induced murine lymphoma , 2014, Proceedings of the National Academy of Sciences.
[7] E. Campo,et al. Synergistic antitumor activity of lenalidomide with the BET bromodomain inhibitor CPI203 in bortezomib-resistant mantle cell lymphoma , 2014, Leukemia.
[8] G. Salles,et al. PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma. , 2014, The New England journal of medicine.
[9] R. Beroukhim,et al. BET Bromodomain Inhibition of MYC-Amplified Medulloblastoma , 2013, Clinical Cancer Research.
[10] Charles Y. Lin,et al. Discovery and characterization of super-enhancer-associated dependencies in diffuse large B cell lymphoma. , 2013, Cancer cell.
[11] R. Young,et al. Super-Enhancers in the Control of Cell Identity and Disease , 2013, Cell.
[12] J. Noel,et al. Abstract C244: Development of the BET bromodomain inhibitor OTX015. , 2013 .
[13] A. Rosenwald,et al. PRDM1/BLIMP1 is commonly inactivated in anaplastic large T-cell lymphoma. , 2013, Blood.
[14] A. Schambach,et al. Bromo- and Extraterminal Domain Chromatin Regulators Serve as Cofactors for Murine Leukemia Virus Integration , 2013, Journal of Virology.
[15] T. Clozel,et al. Mechanism-based epigenetic chemosensitization therapy of diffuse large B-cell lymphoma. , 2013, Cancer discovery.
[16] M. Kersten,et al. High prevalence of oncogenic MYD88 and CD79B mutations in diffuse large B-cell lymphomas presenting at immune-privileged sites , 2013, Blood Cancer Journal.
[17] N. Gray,et al. A mutation in MYD88 (L265P) supports the survival of lymphoplasmacytic cells by activation of Bruton tyrosine kinase in Waldenström macroglobulinemia. , 2013, Blood.
[18] J. Garin,et al. Identification of a novel BET bromodomain inhibitor-sensitive, gene regulatory circuit that controls Rituximab response and tumour growth in aggressive lymphoid cancers , 2013, EMBO molecular medicine.
[19] S. Knapp,et al. PFI-1, a highly selective protein interaction inhibitor, targeting BET Bromodomains. , 2013, Cancer research.
[20] L. Staudt,et al. II. Therapy of DLBCL based on genomics , 2013, Hematological oncology.
[21] Yanwen Jiang,et al. Mechanisms of epigenetic deregulation in lymphoid neoplasms. , 2013, Blood.
[22] Peter Houghton,et al. A Proposal Regarding Reporting of In Vitro Testing Results , 2013, Clinical Cancer Research.
[23] David A. Orlando,et al. Selective Inhibition of Tumor Oncogenes by Disruption of Super-Enhancers , 2013, Cell.
[24] X. Zhao,et al. Disruption of the MYC-miRNA-EZH2 loop to suppress aggressive B-cell lymphoma survival and clonogenicity , 2013, Leukemia.
[25] C. Thieblemont,et al. MYC, BCL2, BCL6 in DLBCL: impact for clinics in the future? , 2013, Blood.
[26] K. Stegmaier,et al. Targeting MYCN in neuroblastoma by BET bromodomain inhibition. , 2013, Cancer discovery.
[27] Reid C Thompson,et al. Inhibition of BET Bromodomain Targets Genetically Diverse Glioblastoma , 2013, Clinical Cancer Research.
[28] H. Varmus,et al. Sensitivity of human lung adenocarcinoma cell lines to targeted inhibition of BET epigenetic signaling proteins , 2012, Proceedings of the National Academy of Sciences.
[29] Christopher J. Ott,et al. BET bromodomain inhibition targets both c-Myc and IL7R in high-risk acute lymphoblastic leukemia. , 2012, Blood.
[30] P. K. Bajpe,et al. Targeting the epigenome for treatment of cancer , 2012, Oncogene.
[31] Tony Kouzarides,et al. Targeting epigenetic readers in cancer. , 2012, The New England journal of medicine.
[32] K. Hoang-Xuan,et al. Recurrent Mutations of MYD88 and TBL1XR1 in Primary Central Nervous System Lymphomas , 2012, Clinical Cancer Research.
[33] Paul Shinn,et al. Exploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphoma. , 2012, Cancer cell.
[34] S. Robson,et al. Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia , 2011, Nature.
[35] P. Sandy,et al. Targeting MYC dependence in cancer by inhibiting BET bromodomains , 2011, Proceedings of the National Academy of Sciences.
[36] R. Young,et al. BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc , 2011, Cell.
[37] C. Reeder,et al. Novel therapeutic agents for B-cell lymphoma: developing rational combinations. , 2011, Blood.
[38] C. Rice,et al. Suppression of inflammation by a synthetic histone mimic , 2010, Nature.
[39] Douglas H. Thamm,et al. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy , 2010, Proceedings of the National Academy of Sciences.
[40] C. Glass,et al. Simple combinations of lineage-determining transcription factors prime cis-regulatory elements required for macrophage and B cell identities. , 2010, Molecular cell.
[41] Cole Trapnell,et al. Ultrafast and memory-efficient alignment of short DNA sequences to the human genome , 2009, Genome Biology.
[42] Suzanne F. Jones,et al. Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a phase I tumor pharmacodynamic study in patients with advanced solid tumors. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[43] R. Lotan,et al. Interaction Index and Different Methods for Determining Drug Interaction in Combination Therapy , 2007, Journal of biopharmaceutical statistics.
[44] J. Davis. Bioinformatics and Computational Biology Solutions Using R and Bioconductor , 2007 .
[45] Pablo Tamayo,et al. Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[46] F. Cavalli,et al. In vitro activity of cyclin-dependent kinase inhibitor CYC202 (Seliciclib, R-roscovitine) in mantle cell lymphomas. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.
[47] R. Momparler. Pharmacology of 5-Aza-2'-deoxycytidine (decitabine). , 2005, Seminars in hematology.
[48] B. Bonavida,et al. Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20 mAb) in non-Hodgkin's lymphoma: implications in chemosensitization and therapeutic intervention , 2005, Oncogene.
[49] Thomas L. Rothstein,et al. Eμ-BRD2 transgenic mice develop B-cell lymphoma and leukemia , 2004 .
[50] Gordon K Smyth,et al. Statistical Applications in Genetics and Molecular Biology Linear Models and Empirical Bayes Methods for Assessing Differential Expression in Microarray Experiments , 2011 .
[51] Cheng Li,et al. Adjusting batch effects in microarray expression data using empirical Bayes methods. , 2007, Biostatistics.
[52] Robert D Cardiff,et al. E mu-BRD2 transgenic mice develop B-cell lymphoma and leukemia. , 2004, Blood.